Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
2008 ◽
Vol 26
(15_suppl)
◽
pp. 2530-2530
◽
2008 ◽
Vol 14
(7)
◽
pp. 2075-2081
◽
2014 ◽
Vol 20
(24)
◽
pp. 6284-6294
◽
2019 ◽
Vol 25
(18)
◽
pp. 5475-5484
◽
2009 ◽
Vol 15
(7)
◽
pp. 2552-2558
◽
2010 ◽
Vol 67
(5)
◽
pp. 1119-1128
◽
2005 ◽
Vol 23
(16_suppl)
◽
pp. 3002-3002
◽